Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan
https://doi.org/10.18705/1607-419X-2011-17-4-325-332
Abstract
The article focuses on antihypertensive effect, organoprotection properties and clinical use of angiotensin II receptor antagonist valsartan in patients with cardiovascular diseases.
About the Authors
Y. V. Sviryaev
Almazov Federal Heart, Blood and Endocrinology Centre, St Petersburg
Russian Federation
Russian Federation
N. E. Zvartau
Almazov Federal Heart, Blood and Endocrinology Centre, St Petersburg
Russian Federation
Russian Federation
References
1. Tigerstedt R., Bergman P. Niere und Kreislauf // Skand. Arch. Physiol. - 1898. - Vol. 8. - P. 223-271.
2.
3. Skeggs L.T. Jr, Lentz K.E., Kahn J.R., Shumway N.P., Woods K.R. The amino acid sequence of hypertensin // II J. Exp. Med. - 1956. - Vol. 104. - P. 193-197.
4.
5. Kageyama R., Ohkubo H., Nakanishi S. Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence // Biochemistry. - 1984. - Vol. 23, № 16. - P. 3603-3609.
6.
7. Braun-Menendez E., Page I.H. Suggested revision of nomenclature - angiotensin // Science. - 1958. - Vol. 127. - P. 242.
8.
9. Braun-Menendez E., Fasciolo J.C., Leloir L.F., Muñoz J.M. The substance causing renal hypertension // J. Physiol. - 1940. - Vol. 98, № 3. - P. 283-298.
10.
11. Page I.H., Helmer O.M. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator // J. Exp. Med. - 1940. - Vol. 71, № 1. - P. 29-42.
12.
13. Skeggs L.T. Jr, Marsh W.H., Kahn J.R., Shumway N.P. The existence of two forms of hypertension // J. Exp. Med. - 1957A. - Vol. 99, № 3. - P. 275-282.
14.
15. Gross F. Renin und hypertensin, physiologische oder pathologische Wirkstoffe? // Klin. Wochenschr. - 1958. - Vol. 36. - P. 693-706.
16.
17. Davis J.O. Mechanisms regulating the secretion and metabolism of aldosterone in experimental secondary hyperaldosteronism // Recent Prog. Horm. Res. - 1959. - Vol. 17. - P. 293-352.
18.
19. Skeggs L.T., Dorer F.E., Kahn J.R., Lentz K.E., Levine M. The biochemistry of the renin-angiotensin system and its role in hypertension // Am. J. Med. - 1976. - Vol. 60, № 6. - P. 737-748.
20.
21. Dzau V.J. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis // Hypertension. 2001. Vol. 37, № 4. P. 10471052. <http://www.ncbi.nlm.nih.gov/pubmed/11304501>
22.
23. Lemarie C.A., Paradis P., Schiffrin E.L. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone // J. Mol. Med. - 2008. - Vol. 86, № 6. - P. 673-678.
24.
25. Furuhashi M., Ura N., Takizawa H. et al. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity // J. Hypertens. - 2004. - Vol. 22, № 10. - P. 1977-1982.
26.
27. Jandeleit-Dahm K.A., Tikellis C., Reid C.M. et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes // J. Hypertens. - 2005. - Vol. 23, № 3. - P. 463-473.
28.
29. Kingston R. Blockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivity // J. Hypertens. - 2004. - Vol. 22, № 10. - P. 1867-1868.
30.
31. Kurtz T.W., Klein U. Next generation multifunctional angiotensinreceptor blockers // Hypertens. Res. - 2009. - Vol. 32, № 10. -P. 826-834.
32.
33. Miura S., Fujino M., Hanzawa H. et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor // J. Biol. Chem. - 2006. - Vol. 281, № 28. - Р. 19288-19295.
34.
35. Miura S., Kiya Y., Kanazawa T. et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state // Mol. Endocrinol. - 2008. - Vol. 22, № 1. - P. 139-146.
36.
37. Zou Y., Akazawa H., Qin Y. et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II // Nat. Cell. Biol. - 2004. - Vol. 6, № 6. - P. 499-506.
38.
39. Inada Y., Ojima M., Kanagawa R. et al. Pharmacologic properties of candesartan cilexetil - possible mechanisms of long-term antihypertensiveaction // J. Hum. Hypertens. - 1999. - Vol. 13, Suppl. 1. - P. 75-80.
40.
41. Galkina E., Ley K. Immune and inflammatory mechanisms of atherosclerosis // Annu Rev. Immunol. - 2009. - Vol. 27. - P. 165-197.
42.
43. Scott J. The pathogenesis of atherosclerosis and new opportunities for treatment and prevention // J. Neural Transm. Suppl. - 2002. - № 63. - Р. 1-17.
44.
45. Li J.J., Chen J.L. Inflammation may be a bridge connecting hypertension and atherosclerosis // Med. Hypotheses. - 2005. - Vol. 64, № 5. - Р. 925-929.
46.
47. Dandona P., Kumar V., Aljada A. et al. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action // J. Clin. Endocrinol. Metab. - 2003. - Vol. 88, № 9. - Р. 4496-4501.
48.
49. Manabe S., Okura T., Watanabe S., Fukuoka T., Higaki J. Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension // J. Cardiovasc. Pharmacol. - 2005. - Vol. 46, № 6. - P. 735-739.
50.
51. Ogawa S., Mori T., Nako K. et al. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy // Hypertension. - 2006. -Vol. 47. - P. 699-705.
52.
53. Cianchetti S., Del Fiorentino A., Colognato R. et al. Anti-inflammatory and antioxidant properties of telmisartan in cultured human umbilical vein endothelial cells // Atherosclerosis. - 2008. - Vol. 198, № 1. - P. 22-28.
54.
55. Guerra-Cuesta J.I., Montуn M., Rodrнguez-Feo J.A. et al. Effect of losartan on human platelet activation // J. Hypertens. - 1999. - Vol. 17, № 3. - P. 447-452.
56.
57. Singh R., Singh A.K., Alavi N., Leehey D.J. Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose // J. Am. Soc. Nephrol. - 2003. - Vol. 14, № 4. - P. 873-880.
58.
59. Konstam M.A., Patten R.D., Thomas I. et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure. Results of the ELITE ventricular function substudy // Am. Heart J. - 2000. - Vol. 139, № 6. - P. 1081-1087.
60.
61. McDonald K.M., Garr M., Carlyle P.F. et al. Relative effects of a1-adrenergic blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog // Circulation. - 1994. - Vol. 90, № 6. - P. 3034-3046.
62.
63. Pourdjabbar A., Parker T.G., Nguyen Q.T. et al. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: Effect of dose on survival, ventricular arrhythmias, function and remodeling // Am. J. Physiol. Heart Circ. Physiol. - 2005. - Vol. 288, № 4. - P. H1997-H2005.
64.
65. Sawicki G., Menon V., Jugdutt B.I. Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade // J. Cardiac Fail. - 2004. - Vol. 10, № 5. - P. 442-449.
66.
67. Solomon S.D., Skali H., Anavekar N.S. et al. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction // Circulation. - 2005. - Vol. 111, № 25. - P. 3411-3419.
68.
69. Wachtell K., Okin P.M., Olsen M.H. et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study // Circulation. - 2007. - Vol. 116, № 7. - P. 700-705.
70.
71. Klingbeil A.U., Schneider M., Martus P., Messerli F.H., Schmieder R.E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension // Am. J. Med. - 2003. - Vol. 115, № 1. -P. 41-46.
72.
73. Neutel J <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Weber M <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Pool J <http://www.ncbi.nlm.nih.gov/pubmed?term=>. et al. Valsartan, a new angiotensin II an tagonist: antihypertensive effects over 24 hours // Clin. Ther. <http://www.ncbi.nlm.nih.gov/pubmed/9220209> - 1997. - Vol. 19, № 3. - P. 447-458; discussion 367-368.
74.
75. Hermida R.C <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Calvo C <http://www.ncbi.nlm.nih.gov/pubmed?term=>., Ayala D.E <http://www.ncbi.nlm.nih.gov/pubmed?term=>. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects // Hypertension. <http://www.ncbi.nlm.nih.gov/pubmed/12874091> - 2003. - Vol. 42, № 3. - Р. 283-290.
76.
77. Berdecchia P., Porcellati C., Schillaci G. et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension // Hypertension. - 1994. -Vol. 24, № 6. - P. 793-801.
78.
79. Staessen J.A., Thijs L., Fagard R. et al., for the Systolic Hypertension in Europe (Syst-Eur) trial investigators. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension // J. Am. Med. Assoc. - 1999. - Vol. 282, № 6. - P. 539-546.
80.
81. Ohkubo T., Hozawa A., Yamaguchi J. et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study // J. Hypertens. - 2002. - Vol. 20, № 11. - P. 2183-2189.
82.
83. Mclnnes G.T. Angiotensin II antagonism in clinical practice: experience with valsartan // J. Cardiovasc. Pharmacol. - 1999. - Vol. 33, Suppl. 1. - P. 29-32.
84.
85. Malacco E., Santonastaso M., Vari N.A. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study // Clin. Ther. - 2004. - Vol. 26, № 6. - P. 855-865.
86.
87. Viberti G., Wheeldon N.M., for the (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect // Circulation. - 2002. - Vol. 106, № 6. - P. 672−678.
88.
89. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial // Lancet. - 2004. - Vol. 363, № 9426. - P. 2022-2031.
90.
91. Vaney C., Waeber B., Turini G., Margalith D., Brunner H.R., Perret C. Renin and the complications of acute myocardial infarction // Chest. - 1984. - Vol. 86, № 1. - P. 40-43.
92.
93. Remes J. Neuroendocrine activation after myocardial infarction // Br. Heart J. - 1994. - Vol. 72, № 3, Suppl.. - P. S65-S69.
94.
95. Isnard R., Pousset F., Trochu J. et al. Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure // Am. J. Cardiol. - 2000. - Vol. 86, № 4. - P. 417-421.
96.
97. Perondi R., Saino A., Tio R.A. et al. ACE inhibition attenuates sympathetic coronary vasoconstriction in patients with coronary artery disease // Circulation. - 1992. - Vol. 85, № 6. - P. 2004-2013.
98.
99. Lonn E.M., Yusuf S., Jha P. et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection // Circulation. - 1994. - Vol. 90, № 4. - P. 2056-2069.
100.
101. Weber K.T., Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system // Circulation. - 1991. - Vol. 83, № 6. - P. 1849-1865.
102.
103. Pfeffer M.A., McMurray J.J., Velazquez E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both // N. Engl. J. Med. - 2003. - Vol. 349, № 20. - P. 1893-1906.
104.
105. White H.D., Aylward P.E., Huang Z. et al.; VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial <http://www.ncbi.nlm.nih.gov/pubmed/16301343> (VALIANT) // Circulation. - 2005. - Vol. 112, № 22. - Р. 3391-3399.
106.
107. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure // J. Am. Coll. Cardiol. - 1992. - Vol. 20, № 1. - P. 248-254.
108.
109. Benedict C.R., Johnstone D.E., Weiner D.H. et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD investigators // J. Am. Coll. Cardiol. - 1994. - Vol. 23, № 6. - P. 1410-1420.
110.
111. Cohn J.N., Tognoni G., Valsartan Heart Failure Trial Investigators.A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. - 2001. - Vol. 345, № 23. - P. 1667-1675.
112.
113. Latini R., Tognoni G., Maggioni A.P. et al. Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group // J. Am. Coll. Cardiol. - 2000. - Vol. 35, № 7. - P. 1801-1807.
114.
115. Maggioni A.P., Latini R. The angiotensin-receptor blockers: from antihypertensives to cardiovascular all-round medications in 10 years? // Blood Press. - 2002. - Vol. 11, № 6. - P. 328-338.
116.
117. Cuspidi C., Negri F., Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: Focus on left ventricular hypertrophy regression and atrial fibrillation prevention // Vasc. Health Risk Manag. - 2008. - Vol. 4, № 1. - P. 67-73.
118.
119. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimates // Am. J. Cardiol. - 1998. - Vol. 82, № 8А. - P. 2N-9N.
120.
121. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program // Am. Heart J. - 2006. - Vol. 151, № 5. - P. 985-991.
122.
123. Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart J. - 2005. - Vol. 149, № 3. - P. 548-557.
124.
125. Schmieder R.E., Kjeldsen S.E., Julius S. et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: The VALUE trial // J. Hypertens. - 2008. - Vol. 26, № 3. - P. 403-411.
126.
127. GISSI-AF Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation) Valsartan for prevention of recurrent atrial fibrillation // N. Engl. J. Med. - 2009. - Vol. 360, № 16. - P. 1606-1617.
128.
129. Wogen J., Kreilick C.A., Livornese R.C., Yokoyama K., Frech F. Patient adherence with amlodipine, lisinopril, or valsartan therapy in a usual-care setting // J. Manag. Care Pharm. <http://www.ncbi.nlm.nih.gov/pubmed/14613440> - 2003. - Vol. 9, № 5. - P. 424-429.
130.
Review
For citations:
Sviryaev Y.V., Zvartau N.E. Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(4):325-332. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-4-325-332
Views:
1062
Email this article 